Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.81 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5605857 | 0.94 | KDR (0.82) | KDRMAPK14MAPK11FLT1FLT4 | |
| SCHEMBL5606094 | 0.92 | KDR (0.80) | KDRMAPK14MAPK11 | |
| SCHEMBL5605860 | 0.90 | KDR (1.00) | KDRMAPK14ERBB2FLT1FLT4 | |
| SCHEMBL5596843 | 0.85 | KDR (0.72) | KDRERBB2LCKFGFR1FLT1 | |
| SCHEMBL27888151 | 0.85 | KDR (0.78) | KDRFLT1FLT4 | |
| SCHEMBL5606908 | 0.85 | KDR (0.72) | KDRMAPK14FLT1FLT4 | |
| SCHEMBL6346539 | 0.84 | KDR (0.66) | KDRMAPK14MAPK11ERBB2 | |
| SCHEMBL5605639 | 0.81 | KDR (1.00) | KDRMAPK14ERBB2LCKFGFR1 | |
| SCHEMBL5606960 | 0.80 | KDR (0.80) | KDRERBB2LCKFGFR1FLT1 | |
| SCHEMBL5596370 | 0.79 | KDR (0.80) | KDRMAPK14ERBB2LCKFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1543009-A4 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | BHIDE RAJEEV S | 2005-10-20 | — | — | US | disclosed |
| US-6951859-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1543009-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004013145-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | KDR 7/4885MAPK14 332/4885MAPK11 352/4885 |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | KDR 7/4885MAPK14 350/4885MAPK11 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.